Triana Biomedicines

Triana Biomedicines develops small molecule therapeutics to treat a variety of previously undruggable or poorly addressed diseases with a focus on oncology. The company’s approach entails the discovery and development of molecular glues–a molecule that facilitates interaction between two non-interacting proteins–through its AI platform. The platform is reportedly capable of identifying over 600 E3 ubiquitin ligases to address disease-specific targets.

Funding and financials

In April 2022, Triana had emerged from stealth with USD 110 million in Series A financing led by Lightspeed Venture Partners. Pfizer Ventures had also participated in the round. The proceeds from the round were said to be earmarked for fuelling the company’s R&D and expansion efforts.